AstraZeneca is continuing with its acquisition and deals spree as it inks yet another license agreement and collaboration deal with Inovio Pharmaceuticals. The deal has been inked between AstraZeneca’s MedImmune and Inovio…
Tag: AstraZeneca
AstraZeneca inks two immuno-oncology deals for novel combination treatments
Just days after selling divesting Caprelsa in a $300 million deal, AstraZeneca has announced two back-to-back immuno-oncology deals with Mirati Therapeutics and Heptares Therapeutics in a bid to explore novel combination treatments….
AstraZeneca to divest Caprelsa; inks $300 million deal with Sanofi’s Genzyme
In a major divestment move AstraZeneca has decided to transfer the global rights to sell and develop Caprelsa to Genzyme – a deal that will see the former net $300 million. Caprelsa…
AstraZeneca, Lilly collaborate for immuno-oncology combination clinical trial in solid tumours
AstraZeneca and Eli Lilly and Company (Lilly) have revealed about their collaboration for clinical trials to evaluate the safety and preliminary efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination…
BRCA-targeting drug shows promise for prostate cancer treatment
According to results of a major trial of a BRCA-targeting drug, men with prostate cancer can benefit from treatment with the pioneering drug olaparib – the first cancer drug to target inherited…
AstraZeneca’s lung cancer drug delays disease progression by over a year
AstraZeneca has revealed latest data from the ongoing AURA study of AZD9291 [a drug for lung cancer] in patients with advanced epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer…